Moreover, diabetes is a major contributing factor to diabetic kidney disease (DKD) for which the ASK1 inhibitor selonsertib slowed diabetic kidney disease progression in a clinical trial with DKD patients [99]. Here, MAP3K5 is linked to diabetic kidney disease.